Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.18 - $3.51 $36 - $702
-200 Reduced 66.67%
100 $0
Q1 2022

May 04, 2022

BUY
$2.26 - $3.84 $225 - $384
100 Added 50.0%
300 $1,000
Q1 2020

May 18, 2020

BUY
$5.5 - $12.3 $1,100 - $2,460
200 New
200 $1,000

Others Institutions Holding CFRX

About CONTRAFECT Corp


  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.